PLEASANTON, Calif., 6. Aug. 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), der Life-Science-Technologieführer mit Fokus auf die Beschleunigung der Wissenschaft und die Verbesserung der menschlichen Gesundheit, gab heute die Finanzergebnisse für das zweite Quartal zum 30. Juni 2026 bekannt.
Die Zusammenarbeit zielt darauf ab, Biomarker zu identifizieren, die die Behandlungsantwort über mehrere Krebsarten vorhersagen, unter Nutzung der Single-Cell- und Spatial-Plattformen von 10x. PLEASANTON, Calif., 29. Juli 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), der Life-Science-Technologieführer mit Fokus auf die Beschleunigung der Wissenschaft und die Förderung der menschlichen ...
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a n...
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutio...
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.